What proportion of patients with heart failure and preserved ejection fraction are eligible for empagliflozin?

J Cardiovasc Med (Hagerstown). 2022 Aug 1;23(8):567-569. doi: 10.2459/JCM.0000000000001331.
No abstract available

Publication types

  • Letter

MeSH terms

  • Benzhydryl Compounds / adverse effects
  • Glucosides* / adverse effects
  • Heart Failure* / diagnosis
  • Heart Failure* / drug therapy
  • Humans
  • Stroke Volume

Substances

  • Benzhydryl Compounds
  • Glucosides
  • empagliflozin